K2M Group (KTWO) Given Buy Rating at Barclays

K2M Group (NASDAQ:KTWO)‘s stock had its “buy” rating reaffirmed by research analysts at Barclays in a note issued to investors on Tuesday. They currently have a $25.00 price objective on the medical device company’s stock. Barclays’ price target would suggest a potential upside of 23.40% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of K2M Group from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Wednesday, October 4th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $28.00 price objective on shares of K2M Group in a research note on Thursday, September 28th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $26.00 price objective on shares of K2M Group in a research note on Friday, September 22nd. UBS Group reaffirmed a “buy” rating and issued a $24.00 price objective (down previously from $26.00) on shares of K2M Group in a research note on Tuesday, October 10th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $27.00 price objective on shares of K2M Group in a research note on Friday, October 20th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $24.50.

Shares of K2M Group (NASDAQ:KTWO) traded down $0.44 during trading on Tuesday, hitting $20.26. 137,390 shares of the stock were exchanged, compared to its average volume of 451,540. K2M Group has a 12 month low of $16.44 and a 12 month high of $25.99. The stock has a market cap of $889.97, a PE ratio of -21.10 and a beta of 1.34. The company has a quick ratio of 1.67, a current ratio of 3.06 and a debt-to-equity ratio of 0.29.

K2M Group (NASDAQ:KTWO) last announced its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.01). K2M Group had a negative net margin of 16.22% and a negative return on equity of 16.02%. The business had revenue of $62.65 million during the quarter, compared to analysts’ expectations of $62.69 million. During the same period last year, the company posted ($0.19) EPS. K2M Group’s revenue for the quarter was up 5.6% on a year-over-year basis. analysts predict that K2M Group will post -0.85 earnings per share for the current year.

Large investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA raised its holdings in K2M Group by 5,175.3% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,484 shares of the medical device company’s stock valued at $109,000 after buying an additional 4,399 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in K2M Group by 7,765.0% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 4,719 shares of the medical device company’s stock valued at $100,000 after buying an additional 4,659 shares during the last quarter. Rockefeller Financial Services Inc. bought a new stake in K2M Group during the 3rd quarter valued at $105,000. Dorsey & Whitney Trust CO LLC bought a new stake in K2M Group during the 2nd quarter valued at $211,000. Finally, Legal & General Group Plc raised its holdings in K2M Group by 41.4% during the 2nd quarter. Legal & General Group Plc now owns 9,561 shares of the medical device company’s stock valued at $232,000 after buying an additional 2,798 shares during the last quarter. Institutional investors own 97.95% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.com-unik.info/2018/01/09/k2m-group-ktwo-given-buy-rating-at-barclays.html.

About K2M Group

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Analyst Recommendations for K2M Group (NASDAQ:KTWO)

Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit